We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Synairgen (SNG) ORD GBP 0.01

Sell:190.60p Buy:191.50p 0 Change: 2.70p (1.40%)
FTSE AIM 100:1.35%
Market closed Prices as at close on 14 January 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:190.60p
Buy:191.50p
Change: 2.70p (1.40%)
Market closed Prices as at close on 14 January 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:190.60p
Buy:191.50p
Change: 2.70p (1.40%)
Market closed Prices as at close on 14 January 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Synairgen plc is a drug discovery and development company. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The Company is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The Company is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The Company offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

Contact details

Address:
Southampton General Hosp, Tremona Road
SOUTHAMPTON
SO16 6YD
United Kingdom
Telephone:
+44 (023) 80512800
Website:
www.synairgen.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 30 September 2021 30/09/21
AGM 18 June 2021 18/06/21
Final results 12 May 2021 12/05/21

General stock information

EPIC:
SNG
ISIN:
GB00B0381Z20
Market cap:
£383.76 million
Shares in issue:
201.34 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • John Ward
    Chief Financial Officer, Executive Director
  • Phillip Monk
    Chief Scientific Officer, Executive Director
  • Richard Marsden
    Chief Executive Officer, Executive Director
  • Gareth Walters
    Chief Regulatory Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.